Drugs / OBI-821
OBI-821
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06490198 | Jul 2024 → Jul 2026 overdue | cholangiocarcinoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02310464 | Dec 2015 → Dec 2020 | breast cancer, colorectal cancer, gastric cancer, lung cancer | OBI Pharma, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00911560 | May 2009 → May 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05442060 | Jul 2022 → Dec 2025 overdue | non-small cell lung carcinoma | OBI Pharma, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05376423 | Jun 2022 → Dec 2024 | esophageal cancer | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04936529 | Aug 2021 → Jun 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03608878 | Apr → Dec 2019 | hepatocellular carcinoma | Chang Gung Memorial Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01516307 | Dec 2011 → Aug 2016 | breast cancer | OBI Pharma, Inc | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03562637 | Dec 2018 → Dec 2025 overdue | triple-negative breast carcinoma | OBI Pharma, Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00693342 | — | fallopian tube cancer, ovarian cancer, peritoneum cancer | Gynecologic Oncology Group | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01223235 | Oct 2010 → Sep 2017 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01349647 Background | May 2011 → Jul 2015 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06057948 Background | Sep 2023 → Mar 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT00857545 Background | Jul 2010 → Sep 2015 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01141491 Comparator | Jun 2010 → Sep 2013 | sarcoma | MabVax Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-821 | “PURPOSE: This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope...” PMID 32718986 ↗ Jul 2020 |
| Known as | Immunologic adjuvant OPT-821 | “Immunologic adjuvant OPT-821” NCT01141491 ↗ |
| Known as | OPT-821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06057948 ↗ |
| Known as | QS-21 | “Comprised of the immunological adjuvant OPT-821 (QS-21)” NCT06057948 ↗ |
| Modality | Other / unclassified | “Saponin-based Immunoadjuvant” NCT00857545 ↗ |
| Route | Subcutaneous | “Given subcutaneously” NCT00693342 ↗ |